Squarepoint’s Cytek Biosciences CTKB Stock Holding History

Squarepoint’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$111K	Buy	+25,296	New	+$119K	﹤0.01%	4049
2025 Q4	–	Sell	-158,641	Closed	-$550K	–	4368
2025 Q3	$550K	Buy	158,641 +13,590	+9%	+$51K	﹤0.01%	3158
2025 Q2	$493K	Buy	145,051 +102,047	+237%	+$340K	﹤0.01%	3294
2025 Q1	$172K	Sell	43,004 -24,911	-37%	-$129K	﹤0.01%	4071
2024 Q4	$441K	Sell	67,915 -42,666	-39%	-$254K	﹤0.01%	3830
2024 Q3	$613K	Sell	110,581 -76,780	-41%	-$435K	﹤0.01%	2952
2024 Q2	$1.05M	Buy	187,361 +170,539	+1,014%	+$1.02M	﹤0.01%	2521
2024 Q1	$113K	Buy	+16,822	New	+$133K	﹤0.01%	3777
2023 Q2	–	Sell	-30,773	Closed	-$283K	–	3632
2023 Q1	$283K	Sell	30,773 -54,660	-64%	-$588K	﹤0.01%	2607
2022 Q4	$872K	Buy	+85,433	New	+$1.15M	﹤0.01%	1915

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Squarepoint's CTKB Position: Q1 2026 in Review

Squarepoint opened a new position in Cytek Biosciences (CTKB) in Q1 2026: 25,296 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #4049 among its holdings. This is a return to the name: Squarepoint previously reported a position in CTKB as recently as Q3 2025.

Squarepoint first reported a position in CTKB in Q4 2022 and has held it in 10 quarters since. The position peaked at $1.05M in Q2 2024. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

Squarepoint held 25,296 shares of Cytek Biosciences worth $111K as of Q1 2026.
Cytek Biosciences was a new Squarepoint position in Q1 2026.
Cytek Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4049 holding.
Squarepoint first reported a position in Cytek Biosciences in Q4 2022 and has held it in 10 quarters since.
Squarepoint's Cytek Biosciences position peaked at $1.05M in Q2 2024.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.